Pfizer
Change company
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
IE
US
US
US
US
US
IN
US
US
US
US
US
US
US
US
US
US
US
US
AU
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
JP
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
BM
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
Track Pfizer in real time with a live news feed covering Pfizer stock news, official press releases, company announcements, and an archive of historical Pfizer news. ...more
Loading news...
Loading more...
12:12 PM | Friday | Sep 11, 2026
Sign in to download news snippet
Holding high-yield dividend stocks like BDCs and REITs in the wrong account silently erases hundreds of dollars every year, and most investors never see it happening until they run the actual numbers.
Read full articleNo data available for this time period.
Change the time range to see results.
Holding high-yield dividend stocks like BDCs and REITs in the wrong account silently erases hundreds of dollars every year, and most investors never see it happening until they run the actual numbers.
Read full article
One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with minimal sales and massive losses.
Read full article
Treasury yields are making income investors work harder than they have in years, and most dividend stocks no longer clear the bar. Six still do, but yield alone is the easy part of the analysis.
Read full article
Novavax NASDAQ: NVAX executives outlined the company's transition from a COVID-19 vaccine-focused business toward a partnership-driven model centered on its Matrix-M adjuvant technology, with near-term attention on Sanofi's commercial rollout of NUVAXOVID, combination vaccine development and early oncology research.
Read full article
Pfizer (PFE) remains a strong buy as guidance is reaffirmed and raised, with acquired assets compounding at 18% operationally. PFE's pipeline strength is evident, especially in obesity (berobenatide) and Vyndamax, providing a bridge over the 2028 LOE trough. Valuation is highly attractive: P/E of 9.11, EV/EBITDA of 8.29, and a 6.
19% dividend yield, with disciplined capital allocation.
California State Teachers Retirement System lifted its holdings in Pfizer Inc. (NYSE: PFE) by 2,320.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 217,981,455 shares of the biopharmaceutical company's stock after purchasing an additional 208,976,273 shares during the quarter. California State
Read full article
PFE's non-COVID growth, oncology pipeline and cost cuts offer a path forward as COVID sales fall and patent losses loom.
Read full article
Collecting $8,900 a month in retirement without selling shares sounds clean until you see what the biggest position in this seven-ticker setup actually pays when markets go quiet.
Read full article
Five S&P 500 stocks—VICI, PFE, VZ, T, F—offer 'safer' high yields, with free cash flow covering dividends and dividends from $1K invested exceeding share prices. Analyst projections indicate the top ten S&P 500 dividend dogs could deliver average net gains of 24.11% by September 2027, with risk/volatility 36% below the market. Dividend dog strategy favors contrarian buys on price pullbacks; most top-yielding stocks become attractive as market corrections bring yields in line with share prices.
Read full article
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 10:45 a.m. EDT. To listen to the webcast, visit our web site at www.
pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today.
The.
No data available for this time period.
Change the time range to see results.